TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate
Benzinga Newsdesk 1 hour ago
NewsEarningsEarnings BeatsEarnings Misses
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 10.71 percent increase over losses of $(0.28) per share
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 10.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $586.000 thousand which beat the analyst consensus estimate of $459.000 thousand by 27.67 percent. This is a 76.66 percent decrease over sales of $2.511 million the same period last year.